Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) changes shares on Tuesday trading session, with a change of 3.60% or $0.09 shares. The trading starts at $2.69 and closed at $2.64 throughout the day. The trading session low price was $2.66 and day high was $2.85 on Tuesday, June 23. After the session, the Healthcare sector daily volume shifted to 0.9 million while its average volume is 1.06M. In other hand, the MRNS market cap reached to $274.81M. While, its current target price is $2.74 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -5.36% and down -10.62% for month. Its quarterly performance was 30.24% above, while its half year performance is up 26.04%. MRNS yearly performance stood at negative -28.22% and rise 26.62% for year-to-date. Current recommendation for Marinus Pharmaceuticals Inc. is 1.40.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. MRNS EPS (TTM) for 12-month is -1.07. EPS for this year is -10.60%, while for the next year its value is -0.58. Its EPS Q/Q reached -33.60%. It has an EPS of 14.50% up for past five years and for the next five years will be up 20.00%.
Let’s take a look on the analyst recommendations on MRNS for the current month and previous month. For the current month, 7 of 8 analysts recommend stock as Buy while 0 as Sell, 1 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 9 analysts participate in stock recommendation. Out of 9, 0 rated it sell, 8 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $4.00-$6.00. Average target price for MRNS was reached at $5.06.
VR Adviser, LLC, Lion Point Capital, LP and Avoro Capital Advisors LLC are the top three holders in Marinus Pharmaceuticals Inc. (MRNS) stock. On Mar 30, 2020, VR Adviser, LLC has 6.5 million shares which valued 13.2 million. On Mar 30, 2020, Lion Point Capital, LP owned 6.37 million shares which valued at 12.94 million. On Mar 30, 2020, Avoro Capital Advisors LLC has a total of 6.2 million shares which valued at 12.59 million. In the end, Avoro Capital Advisors LLC have 7.15% shares outstanding of Marinus Pharmaceuticals Inc. (MRNS) on Mar 30, 2020. The insider ownership moved to 0.63% and institutional holding shifted to 65.80%.
The company posted an EPS (TTM) of -1.07. According to the most recent quarter report on (Jun 2020), 8 analysts estimated an average EPS of -0.19, while -0.24 EPS posted a year ago period. Analyst Estimated EPS for MRNS published in the report was -0.23–0.15 during the same period. Comparing with last year, the average estimated EPS was -0.24 which is higher than -0.32 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for MRNS rise 43.81% for period of 200 days. SMA for 50 days was 16.14% which is showing green signal, while SMA-20 was 1.81%. The moving average value for Marinus Pharmaceuticals Inc. (MRNS) is 2.1665 and 2.5314 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in MRNS stock. On Jan 30, Smith Edward F, CFO, sold 2,380 trading shares at the cost of $2.05, which valued at 4879.0. On Dec 13, Braunstein Scott, Chief Executive Officer, bought 100,000 shares at the cost of $1.25, with total shares of 100,000.